chr12:69201957:> Detail (hg19)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr12:69,201,957-69,239,324 |
| hg38 | chr12:68,808,177-68,845,544 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
| Score | Disease name | Description | Source | Pubmed | Links |
|---|---|---|---|---|---|
| 0.030 | squamous cell carcinoma | Taken together, our data suggest that the interaction of SCYL1BP1/MDM2 could acc... | BeFree,GAD,LHGDN | 25227860 | Detail |
| 0.030 | squamous cell carcinoma | Impact of MDM2 single nucleotide polymorphism on oral squamous cell carcinoma ri... | BeFree,GAD,LHGDN | 25323564 | Detail |
| 0.006 | Carcinoma, Transitional Cell | NA | BeFree,GAD,LHGDN | Detail | |
| 0.003 | Nasopharyngeal carcinoma | The results suggested that the Arg399Gln polymorphism of XRCC1 gene, the 1G/2G p... | BeFree | 25481674 | Detail |
| 0.003 | carcinosarcoma | NA | BeFree,LHGDN | Detail | |
| 0.122 | Neoplastic Cell Transformation | NA | CTD_human,GAD | Detail | |
| 0.080 | Transient ischemic attack | NA | RGD | Detail | |
| 0.002 | Malignant tumor of cervix | To achieve this, AG and TV crude extracts were utilized to screen for apoptosis ... | BeFree | 24993114 | Detail |
| 0.002 | Malignant tumor of cervix | Several factors may contribute to cervical cancer (CC) development, including ge... | BeFree | 25181402 | Detail |
| 0.007 | Uterine Cervical Neoplasm | NA | GAD | Detail | |
| <0.001 | chondrosarcoma | NA | BeFree | Detail | |
| 0.001 | choriocarcinoma | NA | BeFree | Detail | |
| <0.001 | Congenital chromosomal disease | NA | BeFree | Detail | |
| 0.002 | Cocarcinogenesis | NA | GAD | Detail | |
| <0.001 | ulcerative colitis | NA | BeFree | Detail | |
| 0.003 | Colonic Neoplasms | NA | BeFree,LHGDN | Detail | |
| 0.006 | colorectal carcinoma | MDM2 SNP309 polymorphism is associated with colorectal cancer risk. | BeFree | 24797837 | Detail |
| 0.016 | Colorectal Neoplasms | NA | BeFree,GAD,LHGDN | Detail | |
| 0.003 | Crohn Disease | NA | BeFree,GAD | Detail | |
| <0.001 | adenoid cystic carcinoma | NA | BeFree | Detail | |
| <0.001 | Phyllodes Tumor | NA | BeFree | Detail | |
| 0.003 | Cessation of life | NA | LHGDN | Detail | |
| <0.001 | Mental Depression | NA | BeFree | Detail | |
| <0.001 | depressive disorder | NA | BeFree | Detail | |
| 0.080 | Diabetes Mellitus, Experimental | NA | RGD | Detail | |
| 0.002 | DNA Damage | NA | GAD | Detail | |
| 0.010 | Endometrial Neoplasms | NA | GAD,LHGDN | Detail | |
| <0.001 | Ependymoma | NA | BeFree | Detail | |
| 0.003 | Epilepsy, Temporal Lobe | NA | BeFree,LHGDN | Detail | |
| 0.004 | Esophageal Neoplasms | NA | BeFree,GAD | Detail | |
| 0.080 | Fetal Growth Retardation | NA | RGD | Detail | |
| <0.001 | breast fibrocystic disease | NA | BeFree | Detail | |
| <0.001 | fibrosarcoma | NA | BeFree | Detail | |
| 0.002 | Fibrosis | NA | GAD | Detail | |
| <0.001 | Gastritis, Atrophic | NA | BeFree | Detail | |
| <0.001 | gastroesophageal reflux disease | NA | BeFree | Detail | |
| <0.001 | Giant Cell Tumors | NA | BeFree | Detail | |
| 0.021 | glioblastoma | EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeu... | BeFree,GAD,LHGDN | 26200049 | Detail |
| 0.016 | Glioma | It confers glioma cell sensitivity to teniposide through binding to the 3'-UTR r... | BeFree,GAD,LHGDN | 25151861 | Detail |
| 0.016 | Glioma | These findings show that CDKN2 p16 540 C>G, CDKN2 p16 580 C>T and MDM2 SNP309 T>... | BeFree,GAD,LHGDN | 26124340 | Detail |
| <0.001 | Hamartoma | NA | BeFree | Detail | |
| 0.005 | Head and Neck Neoplasms | NA | GAD | Detail | |
| <0.001 | hemangiopericytoma | NA | BeFree | Detail | |
| 0.001 | Hemangiosarcoma | NA | BeFree | Detail | |
| <0.001 | hemochromatosis | NA | BeFree | Detail | |
| 0.001 | hepatitis B | NA | BeFree | Detail | |
| 0.002 | Hepatitis, Viral, Human | NA | GAD | Detail | |
| 0.121 | HIV Infections | Uncommon non-oncogenic HPV genotypes, TP53 and MDM2 genes polymorphisms in HIV-i... | BeFree,CTD_human | 25181402 | Detail |
| 0.006 | Hodgkin Disease | NA | BeFree,LHGDN | Detail | |
| <0.001 | pulmonary hypertension | NA | BeFree | Detail | |
| 0.080 | Hypothermia, natural | NA | RGD | Detail | |
| 0.080 | Ichthyoses | NA | RGD | Detail | |
| 0.120 | male infertility | NA | BeFree,CTD_human | Detail | |
| 0.080 | intermittent claudication | NA | RGD | Detail | |
| 0.001 | Kidney Failure, Acute | NA | BeFree | Detail | |
| 0.002 | Kidney Neoplasm | NA | GAD | Detail | |
| 0.002 | Laryngeal neoplasm | NA | GAD | Detail | |
| <0.001 | Fibroid Tumor | NA | BeFree | Detail | |
| 0.005 | leiomyosarcoma | NA | BeFree,LHGDN | Detail | |
| 0.012 | leukemia | Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analys... | BeFree,GAD,LHGDN | 25169523 | Detail |
| 0.012 | leukemia | Correlations between MDM2 gene SNP309 polymorphism and susceptibility to leukemi... | BeFree,GAD,LHGDN | 25600314 | Detail |
| 0.012 | leukemia | Association of MDM2 polymorphism with risk and prognosis of leukemia: a meta-ana... | BeFree,GAD,LHGDN | 25790771 | Detail |
| 0.019 | chronic lymphocytic leukemia | The anti-leukemic activity of the mitochondria-targeting small molecule sodium d... | BeFree,GAD,LHGDN | 24962518 | Detail |
| 0.019 | chronic lymphocytic leukemia | MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic le... | BeFree,GAD,LHGDN | 25082786 | Detail |
| 0.003 | Acute lymphocytic leukemia | Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia... | BeFree | 24968304 | Detail |
| 0.003 | Acute lymphocytic leukemia | Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rea... | BeFree | 25573381 | Detail |
| 0.002 | Leukemia, Lymphocytic, Acute, L1 | The utility of targeting the p53-MDM2 axis in combination with established drugs... | BeFree | 25573381 | Detail |
| 0.012 | Leukemia, Myelocytic, Acute | TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired... | BeFree,GAD | 25156865 | Detail |
| 0.012 | Leukemia, Myelocytic, Acute | MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian ... | BeFree,GAD | 25361931 | Detail |
| 0.012 | Leukemia, Myelocytic, Acute | Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia devel... | BeFree,GAD | 25854351 | Detail |
| 0.005 | myeloid leukemia | NA | BeFree,GAD | Detail | |
| 0.003 | Myeloid Leukemia, Chronic | NA | BeFree,GAD | Detail | |
| <0.001 | Leukemia, Plasma Cell | NA | BeFree | Detail | |
| <0.001 | Adult T-Cell Lymphoma/Leukemia | NA | BeFree | Detail | |
| <0.001 | leukopenia | NA | BeFree | Detail | |
| 0.003 | Leukoplakia | NA | BeFree,GAD | Detail | |
| 0.005 | lipoma | In whole tissue sections, the medians for MDM2 and CDK4 expression in ALT/WDL we... | BeFree | 24965044 | Detail |
| 0.005 | lipoma | Evaluation of MDM2 overexpression can be used as a useful adjunct to differentia... | BeFree | 25308007 | Detail |
| 0.005 | lipoma | To discriminate lipomas from atypical lipomatous tumor/well-differentiated lipos... | BeFree | 26146760 | Detail |
| 0.024 | liposarcoma | Q-PCR analysis of the liposarcomas revealed the presence of CDK4 amplification i... | BeFree,LHGDN | 25121597 | Detail |
| 0.024 | liposarcoma | To the best of our knowledge, this is the first report of MDM2 FISH amplificatio... | BeFree,LHGDN | 25132684 | Detail |
| 0.024 | liposarcoma | In conclusion, MLPA proves to be an appropriate and straightforward technique fo... | BeFree,LHGDN | 25679065 | Detail |
| 0.001 | liver cirrhosis | NA | BeFree | Detail | |
| <0.001 | Liver Cirrhosis, Alcoholic | NA | BeFree | Detail | |
| 0.080 | Liver diseases | NA | RGD | Detail | |
| 0.008 | Liver neoplasms | NA | BeFree,GAD | Detail | |
| 0.002 | Chronic Obstructive Airway Disease | NA | GAD | Detail | |
| 0.030 | Lung Neoplasms | NA | BeFree,GAD,LHGDN | Detail | |
| 0.002 | Lymphatic Metastasis | NA | GAD | Detail | |
| 0.009 | lymphoma | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | Lymphoma, Follicular | NA | BeFree | Detail | |
| 0.005 | Lymphoma, Non-Hodgkin | NA | GAD | Detail | |
| <0.001 | Lymphoproliferative Disorders | The pool of apoptosis regulator proteins (p53, PUMA, p21, and MDM2) in the bone ... | BeFree | 24824714 | Detail |
| 0.002 | Animal Mammary Neoplasms | NA | GAD | Detail | |
| 0.002 | medulloblastoma | NA | BeFree | Detail | |
| 0.132 | melanoma | NA | BeFree,CTD_human,GAD | Detail | |
| 0.003 | meningioma | NA | BeFree,GAD | Detail | |
| <0.001 | Mesothelioma | NA | BeFree | Detail | |
| 0.004 | Mixed Salivary Gland Tumor | NA | BeFree,LHGDN | Detail | |
| 0.012 | Mouth Neoplasms | NA | GAD | Detail | |
| 0.002 | multiple myeloma | NA | BeFree | Detail | |
| 0.080 | Myocardial Reperfusion Injury | NA | RGD | Detail | |
| <0.001 | myoepithelioma | NA | BeFree | Detail | |
| 0.005 | Nasopharyngeal Neoplasms | NA | GAD | Detail | |
| 0.015 | Neoplasm Metastasis | A requirement for Mouse Double Minute 2 (MDM2) oncogene activation has been sugg... | BeFree,GAD,LHGDN | 25271708 | Detail |
| 0.002 | Neoplasm Recurrence, Local | NA | GAD | Detail | |
| <0.001 | Neoplasms, Connective Tissue | NA | BeFree | Detail | |
| <0.001 | neurilemmoma | NA | BeFree | Detail | |
| 0.016 | neuroblastoma | NA | BeFree,GAD | Detail | |
| <0.001 | Neurofibromatosis 2 | NA | BeFree | Detail | |
| 0.002 | acoustic neuroma | NA | GAD | Detail | |
| <0.001 | neutropenia | NA | BeFree | Detail | |
| <0.001 | Nevus | NA | BeFree | Detail | |
| <0.001 | Melanocytic nevus | NA | BeFree | Detail | |
| 0.002 | Occupational Diseases | NA | GAD | Detail | |
| <0.001 | Odontogenic Tumors | NA | BeFree | Detail | |
| 0.003 | oligodendroglioma | NA | BeFree,GAD | Detail | |
| 0.012 | osteosarcoma | The association of MDM2 c.346G>A genetic variant with the risk of osteosarcoma i... | BeFree,GAD | 25551700 | Detail |
| 0.012 | osteosarcoma | Therefore, when compared with low-grade central and parosteal osteosarcomas, MDM... | BeFree,GAD | 25680902 | Detail |
| 0.005 | ovarian carcinoma | In contrast, the less frequent SNP285G>C; rs117039649, which is in complete link... | BeFree | 25431177 | Detail |
| 0.008 | Pancreatic Neoplasm | NA | BeFree,GAD,LHGDN | Detail | |
| 0.080 | pancreatitis | NA | RGD | Detail | |
| <0.001 | papilloma | NA | BeFree | Detail | |
| <0.001 | Parathyroid Neoplasms | NA | BeFree | Detail | |
| 0.120 | Peripheral neuropathy | NA | CTD_human | Detail | |
| 0.002 | Pharyngeal Neoplasms | NA | GAD | Detail | |
| <0.001 | polycythemia vera | NA | BeFree | Detail | |
| <0.001 | polyps | NA | BeFree | Detail | |
| 0.121 | Precancerous Conditions | NA | BeFree,CTD_human | Detail | |
| 0.080 | priapism | NA | RGD | Detail | |
| 0.128 | Prostatic Neoplasms | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
| <0.001 | retinal detachment | NA | BeFree | Detail | |
| 0.008 | retinoblastoma | NA | BeFree,GAD | Detail | |
| 0.013 | rhabdomyosarcoma | NA | BeFree,LHGDN | Detail | |
| 0.003 | Salivary Gland Neoplasms | NA | LHGDN | Detail | |
| <0.001 | Kaposi sarcoma | NA | BeFree | Detail | |
| <0.001 | Seizures | To discriminate lipomas from atypical lipomatous tumor/well-differentiated lipos... | BeFree | 26146760 | Detail |
| <0.001 | seminoma | NA | BeFree | Detail | |
| <0.001 | Sezary syndrome | NA | BeFree | Detail | |
| 0.009 | Skin Neoplasms | NA | GAD | Detail | |
| 0.002 | Soft Tissue Neoplasms | Using FISH as gold standard, MLPA showed a sensitivity of 90% (36/40) and a spec... | BeFree | 25679065 | Detail |
| 0.008 | Stomach Neoplasms | NA | BeFree,GAD,LHGDN | Detail | |
| 0.080 | post-traumatic stress disorder | NA | RGD | Detail | |
| 0.003 | synovial sarcoma | NA | BeFree,LHGDN | Detail | |
| <0.001 | synovitis | NA | BeFree | Detail | |
| <0.001 | Giant Cell Arteritis | NA | BeFree | Detail | |
| <0.001 | Thrombocythemia, Essential | NA | BeFree | Detail | |
| 0.006 | Thyroid Neoplasm | NA | BeFree,LHGDN | Detail | |
| <0.001 | Uterine Fibroids | NA | BeFree | Detail | |
| <0.001 | Virus Diseases | NA | BeFree | Detail | |
| <0.001 | vitiligo | NA | BeFree | Detail | |
| <0.001 | common wart | NA | BeFree | Detail | |
| <0.001 | xeroderma pigmentosum | NA | BeFree | Detail | |
| 0.002 | Helicobacter Infections | NA | GAD | Detail | |
| 0.002 | Ichthyosis, X-Linked | NA | BeFree | Detail | |
| 0.006 | B-Cell Lymphomas | NA | BeFree,GAD,LHGDN | Detail | |
| 0.004 | diffuse large B-cell lymphoma | The MDM2 polymorphism SNP309 is associated with clinical characteristics and out... | BeFree,GAD | 24889555 | Detail |
| <0.001 | Low Grade Lymphoma (neoplasm) | NA | BeFree | Detail | |
| <0.001 | Lymphoma, T-Cell, Cutaneous | NA | BeFree | Detail | |
| <0.001 | severe combined immunodeficiency | NA | BeFree | Detail | |
| 0.002 | Choroid Plexus Neoplasms | NA | GAD | Detail | |
| 0.002 | Neoplasms, Second Primary | NA | GAD | Detail | |
| 0.134 | Li-Fraumeni syndrome | The MDM2 285G-309G haplotype is associated with an earlier age of tumour onset i... | BeFree,GAD,LHGDN,ORPHANET | 23884452 | Detail |
| 0.134 | Li-Fraumeni syndrome | To date, all genetic modifiers in LFS have been shown to map to either TP53 or i... | BeFree,GAD,LHGDN,ORPHANET | 25683625 | Detail |
| <0.001 | benign neoplasm | NA | BeFree | Detail | |
| <0.001 | Pancreatitis, Chronic | We investigated TP53 codon 72 and MDM2 SNP 309 polymorphisms in 32 patients with... | BeFree | 25734904 | Detail |
| <0.001 | Epstein-Barr Virus Infections | NA | BeFree | Detail | |
| <0.001 | Squamous cell carcinoma of lung | NA | BeFree | Detail | |
| <0.001 | Oral Cavity Carcinoma | NA | BeFree | Detail | |
| 0.001 | Cutaneous Melanoma | NA | BeFree | Detail | |
| 0.001 | Adenocarcinoma of lung (disorder) | NA | BeFree | Detail | |
| 0.002 | esophageal carcinoma | NA | BeFree | Detail | |
| 0.001 | Malignant neoplasm of mouth | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of oropharynx | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of nasopharynx | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of testis | NA | BeFree | Detail | |
| 0.002 | Malignant neoplasm of brain | NA | GAD | Detail | |
| <0.001 | Secondary malignant neoplasm of lung | NA | BeFree | Detail | |
| 0.008 | Tumor Progression | A requirement for Mouse Double Minute 2 (MDM2) oncogene activation has been sugg... | BeFree | 25271708 | Detail |
| 0.002 | choroid plexus papilloma | NA | GAD | Detail | |
| <0.001 | pleomorphic lipoma | NA | BeFree | Detail | |
| 0.128 | Liposarcoma, Dedifferentiated | Ultrasound-guided fine-needle aspiration of a posterior neck dedifferentiated li... | BeFree,ORPHANET | 25132684 | Detail |
| 0.128 | Liposarcoma, Dedifferentiated | MDM2 amplification was noted in 7/8 (88%) atypical lipomatous tumors/well-differ... | BeFree,ORPHANET | 25446247 | Detail |
| 0.128 | Liposarcoma, Dedifferentiated | Using MLPA, with a cut-off ratio of >2, 36/71 samples (22 atypical lipomatous tu... | BeFree,ORPHANET | 25679065 | Detail |
| 0.002 | Liposarcoma, Pleomorphic | MDM2 amplification was noted in 7/8 (88%) atypical lipomatous tumors/well-differ... | BeFree | 25446247 | Detail |
| 0.002 | Germ cell tumor | NA | BeFree | Detail | |
| <0.001 | Sarcoma, Spindle Cell | Several fusion genes identified by whole transcriptome sequencing in a spindle c... | BeFree | 25176350 | Detail |
| <0.001 | hepatoblastoma | NA | BeFree | Detail | |
| <0.001 | Mixed Tumor, Mullerian | NA | BeFree | Detail | |
| <0.001 | Lipomatous neoplasm | In conclusion, MLPA proves to be an appropriate and straightforward technique fo... | BeFree | 25679065 | Detail |
| <0.001 | Lipomatous neoplasm | MDM2 Amplification in Problematic Lipomatous Tumors: Analysis of FISH Testing Cr... | BeFree | 26146760 | Detail |
| <0.001 | Liposarcoma, Myxoid | Immunohistochemically, MDM2 and CDK4 were positive in WDLS/DDLS but negative in ... | BeFree | 25650275 | Detail |
| <0.001 | parosteal osteosarcoma | MDM2 and CDK4 expression in periosteal osteosarcoma. | BeFree | 25680902 | Detail |
| 0.003 | Rhabdomyosarcoma, Embryonal | NA | BeFree,LHGDN | Detail | |
| <0.001 | embryonal carcinoma | NA | BeFree | Detail | |
| <0.001 | Adenocarcinoma, Clear Cell | NA | BeFree | Detail | |
| <0.001 | Medullary carcinoma | NA | BeFree | Detail | |
| <0.001 | mucoepidermoid carcinoma | NA | BeFree | Detail | |
| <0.001 | cholangiocarcinoma | NA | BeFree | Detail | |
| 0.003 | verrucous carcinoma | NA | BeFree,LHGDN | Detail | |
| 0.003 | Cervical Intraepithelial Neoplasia | NA | BeFree,GAD | Detail | |
| <0.001 | Neoplasms, Neuroepithelial | NA | BeFree | Detail | |
| <0.001 | ganglioneuroblastoma | NA | BeFree | Detail | |
| <0.001 | gliosarcoma | NA | BeFree | Detail | |
| <0.001 | Nerve Sheath Tumors | NA | BeFree | Detail | |
| 0.003 | Angiofibroma | NA | BeFree,LHGDN | Detail | |
| 0.001 | childhood rhabdomyosarcoma | NA | BeFree | Detail | |
| <0.001 | adult soft tissue sarcoma | NA | BeFree | Detail | |
| <0.001 | Adult Acute Myeloblastic Leukemia | NA | BeFree | Detail | |
| <0.001 | pediatric acute myeloblastic leukemia | NA | BeFree | Detail | |
| <0.001 | uveal melanoma | NA | BeFree | Detail | |
| 0.002 | Lip and oral cavity carcinoma | NA | BeFree | Detail | |
| 0.003 | pancreatic carcinoma | In combination treatments, PRIMA-1 enhanced the anti-tumor activity of several c... | BeFree | 24838627 | Detail |
| 0.001 | Gastrointestinal Stromal Tumors | NA | BeFree | Detail | |
| 0.003 | Cancer of Nasopharynx | NA | BeFree,GAD | Detail | |
| <0.001 | Medullary carcinoma of thyroid | NA | BeFree | Detail | |
| <0.001 | Papillary thyroid carcinoma | NA | BeFree | Detail | |
| 0.042 | Malignant neoplasm of lung | DNMT3B overexpression by deregulation of FOXO3a-mediated transcription repressio... | BeFree,GAD | 25122426 | Detail |
| 0.042 | Malignant neoplasm of lung | MDM2 (RS769412) G>A Polymorphism in Cigarette Smokers: a Clue for the Susceptibi... | BeFree,GAD | 25987086 | Detail |
| <0.001 | Mucosa-Associated Lymphoid Tissue Lymphoma | NA | BeFree | Detail | |
| <0.001 | Proliferative vitreoretinopathy | NA | BeFree | Detail | |
| 0.003 | Sepsis | NA | BeFree,GAD | Detail | |
| <0.001 | Multiple tumors | NA | BeFree | Detail | |
| 0.001 | Acute respiratory failure | NA | BeFree | Detail | |
| <0.001 | Retractile Mesenteritis | NA | BeFree | Detail | |
| <0.001 | Disorder of lymph node | NA | BeFree | Detail | |
| <0.001 | Carcinoma breast stage IV | NA | BeFree | Detail | |
| <0.001 | Metastatic osteosarcoma | NA | BeFree | Detail | |
| <0.001 | recurrent childhood acute lymphoblastic leukemia | NA | BeFree | Detail | |
| <0.001 | Disseminated neuroblastoma | NA | BeFree | Detail | |
| <0.001 | Medulloblastoma, Adult | NA | BeFree | Detail | |
| <0.001 | Metastatic melanoma | NA | BeFree | Detail | |
| <0.001 | Cancer of Head and Neck | NA | BeFree | Detail | |
| <0.001 | Liver and Intrahepatic Biliary Tract Carcinoma | The meta-analysis provides a strong evidence for the association between MDM2 T3... | BeFree | 25119589 | Detail |
| 0.003 | Squamous cell carcinoma of esophagus | In this study, we examined the expression of GASC1 and certain GASC1-targeted ge... | BeFree | 25220908 | Detail |
| 0.003 | Squamous cell carcinoma of esophagus | The results of this study suggested that MDM2 and p16 are predictive markers for... | BeFree | 25880782 | Detail |
| 0.001 | Adenocarcinoma Of Esophagus | NA | BeFree | Detail | |
| 0.002 | Solid tumour | NA | BeFree | Detail | |
| <0.001 | stage, non-small cell lung cancer | NA | BeFree | Detail | |
| <0.001 | stage, ovarian epithelial cancer | NA | BeFree | Detail | |
| <0.001 | laryngeal squamous cell carcinoma | NA | BeFree | Detail | |
| <0.001 | Leiomyosarcoma of uterus | NA | BeFree | Detail | |
| 0.003 | Adenocarcinoma of pancreas | NA | BeFree,GAD | Detail | |
| 0.002 | cervix carcinoma | To achieve this, AG and TV crude extracts were utilized to screen for apoptosis ... | BeFree | 24993114 | Detail |
| 0.002 | cervix carcinoma | Several factors may contribute to cervical cancer (CC) development, including ge... | BeFree | 25181402 | Detail |
| 0.002 | Restenosis | NA | GAD | Detail | |
| <0.001 | Tumor necrosis | NA | BeFree | Detail | |
| <0.001 | inflammatory myofibroblastic tumor | NA | BeFree | Detail | |
| <0.001 | Adenocarcinoma, intestinal type | NA | BeFree | Detail | |
| 0.003 | malignant fibrous histiocytoma | NA | BeFree | Detail | |
| <0.001 | spindle cell lipoma | NA | BeFree | Detail | |
| <0.001 | Adenoameloblastoma | NA | BeFree | Detail | |
| 0.001 | anaplastic astrocytoma | NA | BeFree | Detail | |
| <0.001 | anaplastic oligodendroglioma | NA | BeFree | Detail | |
| 0.005 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | Whether adjusted for MCL International Prognostic Index (MIPI) or not, deletions... | BeFree,LHGDN | 26022239 | Detail |
| <0.001 | Human papilloma virus infection | NA | BeFree | Detail | |
| <0.001 | Carcinoma ex pleomorphic adenoma | NA | BeFree | Detail | |
| 0.003 | Malignant neoplasm of liver | The meta-analysis provides a strong evidence for the association between MDM2 T3... | BeFree,GAD | 25119589 | Detail |
| <0.001 | intrahepatic cholangiocarcinoma | NA | BeFree | Detail | |
| <0.001 | malignant mesothelioma | No causal relationship was found between cardiac sarcoma and asbestos exposure, ... | BeFree | 25586016 | Detail |
| <0.001 | Breast Cancer, Familial | NA | BeFree | Detail | |
| 0.003 | Malignant neoplasm of pancreas | In combination treatments, PRIMA-1 enhanced the anti-tumor activity of several c... | BeFree | 24838627 | Detail |
| <0.001 | Benign tumor of salivary gland | NA | BeFree | Detail | |
| <0.001 | Carcinoma of anal margin | NA | BeFree | Detail | |
| <0.001 | Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site | NA | BeFree | Detail | |
| 0.018 | Malignant neoplasm of prostate | NA | BeFree,GAD | Detail | |
| <0.001 | Hematologic Neoplasms | NA | BeFree | Detail | |
| <0.001 | dermatofibrosarcoma protuberans | NA | BeFree | Detail | |
| <0.001 | Nijmegen breakage syndrome | NA | BeFree | Detail | |
| <0.001 | Trisomy 12 | NA | BeFree | Detail | |
| 0.006 | endometrial carcinoma | TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal... | BeFree,GAD | 25316267 | Detail |
| 0.006 | endometrial carcinoma | While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, ... | BeFree,GAD | 25327560 | Detail |
| 0.006 | endometrial carcinoma | SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-... | BeFree,GAD | 26293665 | Detail |
| <0.001 | Secondary malignant neoplasm of liver | NA | BeFree | Detail | |
| <0.001 | Malignant tumor of eye | NA | BeFree | Detail | |
| <0.001 | Benign neurologic neoplasms | NA | BeFree | Detail | |
| <0.001 | Chronic active hepatitis | NA | BeFree | Detail | |
| <0.001 | Sleep Apnea, Obstructive | NA | BeFree | Detail | |
| <0.001 | Granulomatosis | NA | BeFree | Detail | |
| 0.002 | Retinal Neoplasms | NA | GAD | Detail | |
| 0.003 | Hepatitis B, Chronic | NA | BeFree,GAD | Detail | |
| 0.003 | Hepatitis C, Chronic | NA | BeFree,LHGDN | Detail | |
| <0.001 | composite lymphoma | NA | BeFree | Detail | |
| 0.006 | Malignant neoplasm of esophagus | NA | BeFree,GAD | Detail | |
| <0.001 | Thyroid carcinoma | NA | BeFree | Detail | |
| <0.001 | Ewings sarcoma | The dAbd C7 induced rapid and massive EWS cell death through Mdm2 degradation an... | BeFree | 25501132 | Detail |
| 0.002 | Malignant glioma | NA | BeFree | Detail | |
| 0.006 | Osteosarcoma of bone | The association of MDM2 c.346G>A genetic variant with the risk of osteosarcoma i... | BeFree | 25551700 | Detail |
| 0.006 | Osteosarcoma of bone | Therefore, when compared with low-grade central and parosteal osteosarcomas, MDM... | BeFree | 25680902 | Detail |
| <0.001 | Carcinoma of larynx | NA | BeFree | Detail | |
| 0.035 | Carcinogenesis | Therefore, the amplification of MDM2 may attenuate the P53 pathway and promote t... | BeFree | 24797837 | Detail |
| 0.035 | Carcinogenesis | Mouse Double Minute 2 (MDM2) has emerged as a pivotal cellular antagonist of p53... | BeFree | 25323564 | Detail |
| 0.035 | Carcinogenesis | Regarding the oncogenesis of primary brain tumors, it was shown that changes in ... | BeFree | 26124340 | Detail |
| 0.002 | Leukemogenesis | NA | BeFree | Detail | |
| 0.008 | prostate carcinoma | NA | BeFree | Detail | |
| 0.003 | Epithelial ovarian cancer | NA | BeFree,GAD | Detail | |
| <0.001 | Progressive Neoplastic Disease | NA | BeFree | Detail | |
| 0.021 | breast carcinoma | Subcellular localization of Mdm2 expression and prognosis of breast cancer. | BeFree | 24292333 | Detail |
| 0.021 | breast carcinoma | MDM2 molecular imaging for the prediction of chemotherapeutic sensitivity in hum... | BeFree | 25022573 | Detail |
| 0.021 | breast carcinoma | To date, most MDM2 inhibitors have been designed to block the MDM2-p53-binding i... | BeFree | 25271708 | Detail |
| 0.021 | breast carcinoma | A 40-bp insertion/deletion polymorphism of Murine Double Minute2 (MDM2) increase... | BeFree | 25326024 | Detail |
| 0.021 | breast carcinoma | Interaction between p53 mutation and a somatic HDMX biomarker better defines met... | BeFree | 25649770 | Detail |
| 0.021 | breast carcinoma | Most MDM2 inhibitors under development are targeting the MDM2-p53 binding, and h... | BeFree | 25739118 | Detail |
| 0.021 | breast carcinoma | The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the gro... | BeFree | 26229107 | Detail |
| 0.007 | Carcinoma of lung | DNMT3B overexpression by deregulation of FOXO3a-mediated transcription repressio... | BeFree | 25122426 | Detail |
| 0.007 | Carcinoma of lung | MDM2 (RS769412) G>A Polymorphism in Cigarette Smokers: a Clue for the Susceptibi... | BeFree | 25987086 | Detail |
| <0.001 | Ewings sarcoma-primitive neuroectodermal tumor (PNET) | NA | BeFree | Detail | |
| 0.002 | Secondary malignant neoplasm of lymph node | NA | BeFree | Detail | |
| 0.002 | Pregnancy loss | NA | GAD | Detail | |
| 0.002 | colon carcinoma | NA | BeFree | Detail | |
| 0.004 | Carcinoma of bladder | The MDM2 SNP309T>G polymorphism increases bladder cancer risk among Caucasians: ... | BeFree | 25040988 | Detail |
| <0.001 | skin carcinoma | NA | BeFree | Detail | |
| 0.007 | Central neuroblastoma | NA | BeFree | Detail | |
| 0.001 | Malignant neoplasm of kidney | NA | BeFree | Detail | |
| <0.001 | malignant fibrous histiocytoma of bone | NA | BeFree | Detail | |
| <0.001 | Febrile Neutropenia | NA | BeFree | Detail | |
| <0.001 | early pregnancy | NA | BeFree | Detail | |
| <0.001 | Arnold-Chiari Malformation, Type I | NA | BeFree | Detail | |
| <0.001 | Brain Tumor, Primary | Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G P... | BeFree | 26124340 | Detail |
| <0.001 | Well Differentiated Oligodendroglioma | NA | BeFree | Detail | |
| <0.001 | familial retinoblastoma | NA | BeFree | Detail | |
| <0.001 | Malignant Squamous Cell Neoplasm | NA | BeFree | Detail | |
| 0.001 | malignant peripheral nerve sheath tumor | NA | BeFree | Detail | |
| <0.001 | Localized Malignant Neoplasm | NA | BeFree | Detail | |
| <0.001 | malignant pleural mesothelioma | MDM2 is an important prognostic and predictive factor for platin-pemetrexed ther... | BeFree | 25668009 | Detail |
| <0.001 | Helicobacter pylori infection | NA | BeFree | Detail | |
| <0.001 | Invasive breast carcinoma | NA | BeFree | Detail | |
| <0.001 | Pancreatic carcinoma resectable | NA | BeFree | Detail | |
| <0.001 | Retinoblastoma unilateral | NA | BeFree | Detail | |
| <0.001 | Undifferentiated (Embryonal) Sarcoma | NA | BeFree | Detail | |
| <0.001 | Testicular malignant germ cell tumor | NA | BeFree | Detail | |
| <0.001 | breast adenocarcinoma | NA | BeFree | Detail | |
| <0.001 | Advanced cancer | NA | BeFree | Detail | |
| 0.002 | Carcinoma, Pancreatic Ductal | NA | GAD | Detail | |
| 0.004 | ovarian neoplasm | NA | BeFree,GAD | Detail | |
| <0.001 | precancerous lesions | NA | BeFree | Detail | |
| <0.001 | salivary gland carcinoma | NA | BeFree | Detail | |
| 0.009 | Papillomavirus Infections | NA | GAD | Detail | |
| <0.001 | Invasive Ductal Breast Carcinoma | NA | BeFree | Detail | |
| 0.007 | Malignant neoplasm of ovary | In contrast, the less frequent SNP285G>C; rs117039649, which is in complete link... | BeFree,GAD | 25431177 | Detail |
| <0.001 | endometrial adenocarcinoma | NA | BeFree | Detail | |
| 0.001 | Squamous cell carcinoma of the head and neck | NA | BeFree | Detail | |
| 0.038 | sarcoma | Quantitative assessment of the association between HDMX polymorphism and sarcoma... | BeFree,LHGDN | 24972690 | Detail |
| 0.038 | sarcoma | Impact of MDM2 gene polymorphism on sarcoma risk. | BeFree,LHGDN | 25366142 | Detail |
| 0.038 | sarcoma | MDM2/4 antagonists, on the other hand, are likely to be efficacious in malignanc... | BeFree,LHGDN | 25455730 | Detail |
| 0.038 | sarcoma | In this study, we evaluated a role for the HDMX-S/FL ratio as one such biomarker... | BeFree,LHGDN | 25649770 | Detail |
| 0.038 | sarcoma | Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograf... | BeFree,LHGDN | 25832557 | Detail |
| 0.004 | Atypical Lipoma | Recently, a number of tumor-specific chromosome translocations and associated fu... | BeFree | 24965044 | Detail |
| 0.004 | Atypical Lipoma | MDM2 amplification was noted in 7/8 (88%) atypical lipomatous tumors/well-differ... | BeFree | 25446247 | Detail |
| 0.004 | Atypical Lipoma | Four cases of atypical lipomatous tumor/well-differentiated liposarcoma (4/26, 1... | BeFree | 25679065 | Detail |
| 0.004 | Atypical Lipoma | To discriminate lipomas from atypical lipomatous tumor/well-differentiated lipos... | BeFree | 26146760 | Detail |
| <0.001 | spindle cell rhabdomyosarcoma | NA | BeFree | Detail | |
| <0.001 | Intratubular malignant germ cells | NA | BeFree | Detail | |
| <0.001 | spindle cell liposarcoma | NA | BeFree | Detail | |
| <0.001 | Primary Effusion Lymphoma | NA | BeFree | Detail | |
| <0.001 | Precursor B-cell lymphoblastic leukemia | NA | BeFree | Detail | |
| <0.001 | Adenocarcinoma of large intestine | NA | BeFree | Detail | |
| <0.001 | childhood leukemia | MDM2/4 antagonists, on the other hand, are likely to be efficacious in malignanc... | BeFree | 25455730 | Detail |
| <0.001 | Classical Hodgkin's Lymphoma | NA | BeFree | Detail | |
| <0.001 | Desmoplastic melanoma | NA | BeFree | Detail | |
| <0.001 | Hereditary Malignant Neoplasm | NA | BeFree | Detail | |
| <0.001 | gastric cardia adenocarcinoma | NA | BeFree | Detail | |
| <0.001 | gastric cardia carcinoma | NA | BeFree | Detail | |
| <0.001 | Hepatitis B Virus-Related Hepatocellular Carcinoma | NA | BeFree | Detail | |
| <0.001 | Hereditary Nonpolyposis Colorectal Cancer | NA | BeFree | Detail | |
| <0.001 | Human Papillomavirus-Related Esophageal Squamous Cell Carcinoma | NA | BeFree | Detail | |
| <0.001 | Inflammatory malignant fibrous histiocytoma | NA | BeFree | Detail | |
| <0.001 | Invasive Carcinoma | NA | BeFree | Detail | |
| <0.001 | Localized Carcinoma | NA | BeFree | Detail | |
| <0.001 | Oligodendroglial Neoplasm | NA | BeFree | Detail | |
| 0.001 | pancreatic ductal adenocarcinoma | Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal aden... | BeFree | 25734904 | Detail |
| <0.001 | Treatment related acute myeloid leukaemia | NA | BeFree | Detail | |
| <0.001 | differentiated thyroid gland carcinoma | NA | BeFree | Detail | |
| <0.001 | Marginal Zone B-Cell Lymphoma | NA | BeFree | Detail | |
| 0.125 | Liposarcoma, well differentiated | Evaluation of MDM2 overexpression can be used as a useful adjunct to differentia... | BeFree,ORPHANET | 25308007 | Detail |
| 0.125 | Liposarcoma, well differentiated | Four cases of atypical lipomatous tumor/well-differentiated liposarcoma (4/26, 1... | BeFree,ORPHANET | 25679065 | Detail |
| <0.001 | Periosteal Osteosarcoma | MDM2 and CDK4 expression in periosteal osteosarcoma. | BeFree | 25680902 | Detail |
| 0.001 | renal carcinoma | NA | BeFree | Detail | |
| <0.001 | anal squamous cell carcinoma | NA | BeFree | Detail | |
| <0.001 | Cardiomyopathy, Familial Idiopathic | NA | BeFree | Detail | |
| <0.001 | Benign melanocytic nevus | NA | BeFree | Detail | |
| 0.248 | Mammary Neoplasms | NA | BeFree,CTD_human,GAD,LHGDN,RGD | Detail | |
| <0.001 | Breast Cancer Model | The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in b... | BeFree | 25271708 | Detail |
| <0.001 | Hepatocarcinogenesis | NA | BeFree | Detail | |
| <0.001 | Mammary Tumorigenesis | NA | BeFree | Detail | |
| <0.001 | Poorly Differentiated Neuroblastoma | NA | BeFree | Detail | |
| <0.001 | Cancer Cell Growth | NA | BeFree | Detail | |
| <0.001 | Ganglioneuroblastoma, Nodular | NA | BeFree | Detail | |
| <0.001 | Malignant Conversion | NA | BeFree | Detail | |
| <0.001 | Salivary Gland Pleomorphic Adenoma | NA | BeFree | Detail | |
| 0.001 | Tumor Angiogenesis | NA | BeFree | Detail | |
| <0.001 | Tumor Promotion | NA | BeFree | Detail | |
| <0.001 | Xenograft Model | Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograf... | BeFree | 25832557 | Detail |
| 0.017 | colorectal cancer | MDM2 SNP309 polymorphism is associated with colorectal cancer risk. | BeFree,GAD | 24797837 | Detail |
| <0.001 | Rash and Dermatitis Adverse Event Associated with Chemoradiation | NA | BeFree | Detail | |
| 0.002 | Glioblastoma multiforme | NA | BeFree | Detail | |
| <0.001 | Cirrhosis | NA | BeFree | Detail | |
| <0.001 | tumor vasculature | NA | BeFree | Detail | |
| <0.001 | Enchondroma | NA | BeFree | Detail | |
| <0.001 | Intimal sarcoma | In the cardiac sarcoma, MDM2 amplification and CDKN2AB/9p21 biallelic deletion s... | BeFree | 25586016 | Detail |
| <0.001 | Meningioma, benign, no ICD-O subtype | NA | BeFree | Detail | |
| <0.001 | VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding) | NA | BeFree | Detail | |
| 0.004 | uterine corpus cancer | TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal... | BeFree | 25316267 | Detail |
| 0.004 | uterine corpus cancer | While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, ... | BeFree | 25327560 | Detail |
| 0.004 | uterine corpus cancer | SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-... | BeFree | 26293665 | Detail |
| 0.008 | Precursor Cell Lymphoblastic Leukemia Lymphoma | Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia... | BeFree,GAD,LHGDN | 24968304 | Detail |
| 0.008 | Precursor Cell Lymphoblastic Leukemia Lymphoma | Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rea... | BeFree,GAD,LHGDN | 25573381 | Detail |
| <0.001 | Urothelial Carcinoma | NA | BeFree | Detail | |
| 0.022 | liver carcinoma | Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and ... | BeFree,GAD,LHGDN | 25431954 | Detail |
| <0.001 | Oropharyngeal Carcinoma | NA | BeFree | Detail | |
| <0.001 | Pancreatic carcinoma, familial | NA | BeFree | Detail | |
| 0.003 | Nasopharyngeal carcinoma | The results suggested that the Arg399Gln polymorphism of XRCC1 gene, the 1G/2G p... | BeFree | 25481674 | Detail |
| 0.002 | Lipomatosis, Multiple | In whole tissue sections, the medians for MDM2 and CDK4 expression in ALT/WDL we... | BeFree | 24965044 | Detail |
| 0.002 | Lipomatosis, Multiple | Evaluation of MDM2 overexpression can be used as a useful adjunct to differentia... | BeFree | 25308007 | Detail |
| 0.002 | Lipomatosis, Multiple | To discriminate lipomas from atypical lipomatous tumor/well-differentiated lipos... | BeFree | 26146760 | Detail |
| 0.002 | granulomatosis with polyangiitis | NA | GAD | Detail | |
| <0.001 | Progressive cGVHD | NA | BeFree | Detail | |
| <0.001 | Triple Negative Breast Neoplasms | NA | BeFree | Detail | |
| 0.003 | Infection | NA | LHGDN | Detail | |
| <0.001 | Fibromyxosarcoma | NA | BeFree | Detail | |
| <0.001 | Experimental Organism Basal Cell Carcinoma | NA | BeFree | Detail | |
| <0.001 | Abdominal Neoplasms | NA | BeFree | Detail | |
| 0.002 | Spontaneous abortion | NA | GAD | Detail | |
| 0.010 | adenocarcinoma | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | Adenovirus Infections | NA | BeFree | Detail | |
| <0.001 | ameloblastoma | NA | BeFree | Detail | |
| <0.001 | Anaplasia | NA | BeFree | Detail | |
| 0.002 | Anoxia | NA | GAD | Detail | |
| <0.001 | arteriosclerosis | NA | BeFree | Detail | |
| <0.001 | Congenital arteriovenous malformation | NA | BeFree | Detail | |
| 0.006 | rheumatoid arthritis | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | Astrocytoma | NA | BeFree | Detail | |
| 0.001 | ataxia telangiectasia | NA | BeFree | Detail | |
| <0.001 | atherosclerosis | NA | BeFree | Detail | |
| <0.001 | Tooth Attrition | NA | BeFree | Detail | |
| <0.001 | Autoimmune Diseases | NA | BeFree | Detail | |
| 0.018 | Malignant neoplasm of urinary bladder | The MDM2 SNP309T>G polymorphism increases bladder cancer risk among Caucasians: ... | BeFree,GAD | 25040988 | Detail |
| 0.014 | Bladder Neoplasm | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | Blast Phase | NA | BeFree | Detail | |
| 0.001 | Bone neoplasms | NA | BeFree | Detail | |
| 0.012 | Brain Neoplasms | NA | BeFree,GAD | Detail | |
| 0.059 | Malignant neoplasm of breast | Subcellular localization of Mdm2 expression and prognosis of breast cancer. | BeFree,GAD | 24292333 | Detail |
| 0.059 | Malignant neoplasm of breast | MDM2 molecular imaging for the prediction of chemotherapeutic sensitivity in hum... | BeFree,GAD | 25022573 | Detail |
| 0.059 | Malignant neoplasm of breast | To date, most MDM2 inhibitors have been designed to block the MDM2-p53-binding i... | BeFree,GAD | 25271708 | Detail |
| 0.059 | Malignant neoplasm of breast | A 40-bp insertion/deletion polymorphism of Murine Double Minute2 (MDM2) increase... | BeFree,GAD | 25326024 | Detail |
| 0.059 | Malignant neoplasm of breast | Interaction between p53 mutation and a somatic HDMX biomarker better defines met... | BeFree,GAD | 25649770 | Detail |
| 0.059 | Malignant neoplasm of breast | Most MDM2 inhibitors under development are targeting the MDM2-p53 binding, and h... | BeFree,GAD | 25739118 | Detail |
| 0.059 | Malignant neoplasm of breast | The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the gro... | BeFree,GAD | 26229107 | Detail |
| <0.001 | Burkitt lymphoma | NA | BeFree | Detail | |
| 0.002 | Malignant tumor of colon | NA | BeFree | Detail | |
| 0.004 | Malignant neoplasm of endometrium | TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal... | BeFree | 25316267 | Detail |
| 0.004 | Malignant neoplasm of endometrium | While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, ... | BeFree | 25327560 | Detail |
| 0.004 | Malignant neoplasm of endometrium | SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-... | BeFree | 26293665 | Detail |
| <0.001 | Malignant neoplasm of larynx | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of skin | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of thyroid | NA | BeFree | Detail | |
| <0.001 | Bronchogenic Carcinoma | NA | BeFree | Detail | |
| <0.001 | mucinous adenocarcinoma | NA | BeFree | Detail | |
| 0.127 | Non-small cell lung carcinoma | Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in pat... | BeFree,CTD_human | 25482940 | Detail |
| 0.127 | Non-small cell lung carcinoma | Association of p53 and mdm2 in the development and progression of non-small cell... | BeFree,CTD_human | 25672611 | Detail |
| <0.001 | Carcinoma, Papillary | NA | BeFree | Detail | |
| 0.012 | renal cell carcinoma | The T309G MDM2 polymorphism is an independent prognostic factor for patients wit... | BeFree,GAD,LHGDN | 25415135 | Detail |
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| Taken together, our data suggest that the interaction of SCYL1BP1/MDM2 could accelerate MDM2 degrada... | DisGeNET | Detail |
| Impact of MDM2 single nucleotide polymorphism on oral squamous cell carcinoma risk. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The results suggested that the Arg399Gln polymorphism of XRCC1 gene, the 1G/2G polymorphism of MMP-1... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| To achieve this, AG and TV crude extracts were utilized to screen for apoptosis induction, inhibitio... | DisGeNET | Detail |
| Several factors may contribute to cervical cancer (CC) development, including genetic variants such ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| MDM2 SNP309 polymorphism is associated with colorectal cancer risk. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic c... | DisGeNET | Detail |
| It confers glioma cell sensitivity to teniposide through binding to the 3'-UTR region of MDM2 leadin... | DisGeNET | Detail |
| These findings show that CDKN2 p16 540 C>G, CDKN2 p16 580 C>T and MDM2 SNP309 T>G variants and their... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Uncommon non-oncogenic HPV genotypes, TP53 and MDM2 genes polymorphisms in HIV-infected women in Sou... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis. | DisGeNET | Detail |
| Correlations between MDM2 gene SNP309 polymorphism and susceptibility to leukemia. | DisGeNET | Detail |
| Association of MDM2 polymorphism with risk and prognosis of leukemia: a meta-analysis. | DisGeNET | Detail |
| The anti-leukemic activity of the mitochondria-targeting small molecule sodium dichloroacetate (DCA)... | DisGeNET | Detail |
| MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of a... | DisGeNET | Detail |
| Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negati... | DisGeNET | Detail |
| Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lympho... | DisGeNET | Detail |
| The utility of targeting the p53-MDM2 axis in combination with established drugs for the management ... | DisGeNET | Detail |
| TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome. | DisGeNET | Detail |
| MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian study. | DisGeNET | Detail |
| Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In whole tissue sections, the medians for MDM2 and CDK4 expression in ALT/WDL were higher than those... | DisGeNET | Detail |
| Evaluation of MDM2 overexpression can be used as a useful adjunct to differentiate WDLPS from large ... | DisGeNET | Detail |
| To discriminate lipomas from atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDL) we ... | DisGeNET | Detail |
| Q-PCR analysis of the liposarcomas revealed the presence of CDK4 amplification in 44 cases (91.7%) a... | DisGeNET | Detail |
| To the best of our knowledge, this is the first report of MDM2 FISH amplification in a liposarcoma p... | DisGeNET | Detail |
| In conclusion, MLPA proves to be an appropriate and straightforward technique for screening MDM2/CDK... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The pool of apoptosis regulator proteins (p53, PUMA, p21, and MDM2) in the bone marrow, lymph node, ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| A requirement for Mouse Double Minute 2 (MDM2) oncogene activation has been suggested to be associat... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The association of MDM2 c.346G>A genetic variant with the risk of osteosarcoma in Chinese. | DisGeNET | Detail |
| Therefore, when compared with low-grade central and parosteal osteosarcomas, MDM2 and CDK4 markers c... | DisGeNET | Detail |
| In contrast, the less frequent SNP285G>C; rs117039649, which is in complete linkage disequilibrium w... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| To discriminate lipomas from atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDL) we ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Using FISH as gold standard, MLPA showed a sensitivity of 90% (36/40) and a specificity of 100% (31/... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse larg... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The MDM2 285G-309G haplotype is associated with an earlier age of tumour onset in patients with Li-F... | DisGeNET | Detail |
| To date, all genetic modifiers in LFS have been shown to map to either TP53 or its principal negativ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| We investigated TP53 codon 72 and MDM2 SNP 309 polymorphisms in 32 patients with PDAC, 16 patients w... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| A requirement for Mouse Double Minute 2 (MDM2) oncogene activation has been suggested to be associat... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Ultrasound-guided fine-needle aspiration of a posterior neck dedifferentiated liposarcoma with MDM2 ... | DisGeNET | Detail |
| MDM2 amplification was noted in 7/8 (88%) atypical lipomatous tumors/well-differentiated and 3/3 (10... | DisGeNET | Detail |
| Using MLPA, with a cut-off ratio of >2, 36/71 samples (22 atypical lipomatous tumors/well-differenti... | DisGeNET | Detail |
| MDM2 amplification was noted in 7/8 (88%) atypical lipomatous tumors/well-differentiated and 3/3 (10... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Several fusion genes identified by whole transcriptome sequencing in a spindle cell sarcoma with rea... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In conclusion, MLPA proves to be an appropriate and straightforward technique for screening MDM2/CDK... | DisGeNET | Detail |
| MDM2 Amplification in Problematic Lipomatous Tumors: Analysis of FISH Testing Criteria. | DisGeNET | Detail |
| Immunohistochemically, MDM2 and CDK4 were positive in WDLS/DDLS but negative in MLSLC and ordinary M... | DisGeNET | Detail |
| MDM2 and CDK4 expression in periosteal osteosarcoma. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In combination treatments, PRIMA-1 enhanced the anti-tumor activity of several chemotherapic drugs a... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| DNMT3B overexpression by deregulation of FOXO3a-mediated transcription repression and MDM2 overexpre... | DisGeNET | Detail |
| MDM2 (RS769412) G>A Polymorphism in Cigarette Smokers: a Clue for the Susceptibility to Smoking and ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The meta-analysis provides a strong evidence for the association between MDM2 T309G polymorphism and... | DisGeNET | Detail |
| In this study, we examined the expression of GASC1 and certain GASC1-targeted genes (KLF4, MYC, SOX2... | DisGeNET | Detail |
| The results of this study suggested that MDM2 and p16 are predictive markers for chemoradioresistanc... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| To achieve this, AG and TV crude extracts were utilized to screen for apoptosis induction, inhibitio... | DisGeNET | Detail |
| Several factors may contribute to cervical cancer (CC) development, including genetic variants such ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Whether adjusted for MCL International Prognostic Index (MIPI) or not, deletions of RB1, CDKN2A, TP5... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The meta-analysis provides a strong evidence for the association between MDM2 T309G polymorphism and... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| No causal relationship was found between cardiac sarcoma and asbestos exposure, although MDM2 abnorm... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In combination treatments, PRIMA-1 enhanced the anti-tumor activity of several chemotherapic drugs a... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women. | DisGeNET | Detail |
| While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes ... | DisGeNET | Detail |
| SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The dAbd C7 induced rapid and massive EWS cell death through Mdm2 degradation and p53 reactivation. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The association of MDM2 c.346G>A genetic variant with the risk of osteosarcoma in Chinese. | DisGeNET | Detail |
| Therefore, when compared with low-grade central and parosteal osteosarcomas, MDM2 and CDK4 markers c... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Therefore, the amplification of MDM2 may attenuate the P53 pathway and promote tumorigenesis. | DisGeNET | Detail |
| Mouse Double Minute 2 (MDM2) has emerged as a pivotal cellular antagonist of p53 by destructing the ... | DisGeNET | Detail |
| Regarding the oncogenesis of primary brain tumors, it was shown that changes in functions of p16 and... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Subcellular localization of Mdm2 expression and prognosis of breast cancer. | DisGeNET | Detail |
| MDM2 molecular imaging for the prediction of chemotherapeutic sensitivity in human breast cancer xen... | DisGeNET | Detail |
| To date, most MDM2 inhibitors have been designed to block the MDM2-p53-binding interphase, and have ... | DisGeNET | Detail |
| A 40-bp insertion/deletion polymorphism of Murine Double Minute2 (MDM2) increased the risk of breast... | DisGeNET | Detail |
| Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in... | DisGeNET | Detail |
| Most MDM2 inhibitors under development are targeting the MDM2-p53 binding, and have little or no eff... | DisGeNET | Detail |
| The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer... | DisGeNET | Detail |
| DNMT3B overexpression by deregulation of FOXO3a-mediated transcription repression and MDM2 overexpre... | DisGeNET | Detail |
| MDM2 (RS769412) G>A Polymorphism in Cigarette Smokers: a Clue for the Susceptibility to Smoking and ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The MDM2 SNP309T>G polymorphism increases bladder cancer risk among Caucasians: a meta-analysis. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Pati... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant ple... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In contrast, the less frequent SNP285G>C; rs117039649, which is in complete linkage disequilibrium w... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Quantitative assessment of the association between HDMX polymorphism and sarcoma. | DisGeNET | Detail |
| Impact of MDM2 gene polymorphism on sarcoma risk. | DisGeNET | Detail |
| MDM2/4 antagonists, on the other hand, are likely to be efficacious in malignancies in which MDM2 or... | DisGeNET | Detail |
| In this study, we evaluated a role for the HDMX-S/FL ratio as one such biomarker, based on its assoc... | DisGeNET | Detail |
| Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhoo... | DisGeNET | Detail |
| Recently, a number of tumor-specific chromosome translocations and associated fusion genes have been... | DisGeNET | Detail |
| MDM2 amplification was noted in 7/8 (88%) atypical lipomatous tumors/well-differentiated and 3/3 (10... | DisGeNET | Detail |
| Four cases of atypical lipomatous tumor/well-differentiated liposarcoma (4/26, 15%) with a low MDM2 ... | DisGeNET | Detail |
| To discriminate lipomas from atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDL) we ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| MDM2/4 antagonists, on the other hand, are likely to be efficacious in malignancies in which MDM2 or... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Evaluation of MDM2 overexpression can be used as a useful adjunct to differentiate WDLPS from large ... | DisGeNET | Detail |
| Four cases of atypical lipomatous tumor/well-differentiated liposarcoma (4/26, 15%) with a low MDM2 ... | DisGeNET | Detail |
| MDM2 and CDK4 expression in periosteal osteosarcoma. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhoo... | DisGeNET | Detail |
| MDM2 SNP309 polymorphism is associated with colorectal cancer risk. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In the cardiac sarcoma, MDM2 amplification and CDKN2AB/9p21 biallelic deletion suggested intimal sar... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women. | DisGeNET | Detail |
| While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes ... | DisGeNET | Detail |
| SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression ... | DisGeNET | Detail |
| Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negati... | DisGeNET | Detail |
| Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lympho... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepa... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The results suggested that the Arg399Gln polymorphism of XRCC1 gene, the 1G/2G polymorphism of MMP-1... | DisGeNET | Detail |
| In whole tissue sections, the medians for MDM2 and CDK4 expression in ALT/WDL were higher than those... | DisGeNET | Detail |
| Evaluation of MDM2 overexpression can be used as a useful adjunct to differentiate WDLPS from large ... | DisGeNET | Detail |
| To discriminate lipomas from atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDL) we ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The MDM2 SNP309T>G polymorphism increases bladder cancer risk among Caucasians: a meta-analysis. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Subcellular localization of Mdm2 expression and prognosis of breast cancer. | DisGeNET | Detail |
| MDM2 molecular imaging for the prediction of chemotherapeutic sensitivity in human breast cancer xen... | DisGeNET | Detail |
| To date, most MDM2 inhibitors have been designed to block the MDM2-p53-binding interphase, and have ... | DisGeNET | Detail |
| A 40-bp insertion/deletion polymorphism of Murine Double Minute2 (MDM2) increased the risk of breast... | DisGeNET | Detail |
| Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in... | DisGeNET | Detail |
| Most MDM2 inhibitors under development are targeting the MDM2-p53 binding, and have little or no eff... | DisGeNET | Detail |
| The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women. | DisGeNET | Detail |
| While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes ... | DisGeNET | Detail |
| SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small... | DisGeNET | Detail |
| Association of p53 and mdm2 in the development and progression of non-small cell lung cancer. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The T309G MDM2 polymorphism is an independent prognostic factor for patients with RCC, with the TT g... | DisGeNET | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- dbSNP
- rs386493716 dbSNP
- Genome
- hg19
- Position
- chr12:69,201,957-69,239,324
- Variant Type
- snv
Genome browser